T1	Participants 210 306	patients under antihypertensive treatment visit-to-visit (or long-term) variability of clinic BP
T2	Participants 718 863	the hypertensive patients of the European Lacidipine Study on Atherosclerosis (ELSA) trial treated for 4 years with either atenolol or lacidipine
T3	Participants 1308 1315	period.
T4	Participants 1316 1519	Patients in whom at least seven clinic (6-month intervals) or at least three (yearly intervals) 24-h values were available from the end of the drug titration phase to the end of the study were considered
T5	Participants 2313 2356	CONCLUSION In mild-to-moderate hypertensive
